Zhe-Sheng Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6362085/publications.pdf

Version: 2024-02-01

395 papers	21,330 citations	12322 69 h-index	15249 126 g-index
405 all docs	405 docs citations	405 times ranked	20125 citing authors

#	Article	IF	Citations
1	The development of anticancer ruthenium(<scp>ii</scp>) complexes: from single molecule compounds to nanomaterials. Chemical Society Reviews, 2017, 46, 5771-5804.	18.7	793
2	Silver nanoparticles: synthesis, properties, and therapeutic applications. Drug Discovery Today, 2015, 20, 595-601.	3.2	723
3	The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resistance Updates, 2015, 18, 1-17.	6.5	590
4	Biosynthesis of Nanoparticles by Microorganisms and Their Applications. Journal of Nanomaterials, 2011, 2011, 1-16.	1.5	554
5	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resistance Updates, 2016, 27, 14-29.	6.5	511
6	Autophagy and multidrug resistance in cancer. Chinese Journal of Cancer, 2017, 36, 52.	4.9	497
7	Microbiota in health and diseases. Signal Transduction and Targeted Therapy, 2022, 7, 135.	7.1	494
8	Modulating ROS to overcome multidrug resistance in cancer. Drug Resistance Updates, 2018, 41, 1-25.	6.5	420
9	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research, 2008, 68, 7905-7914.	0.4	362
10	Transport of Cyclic Nucleotides and Estradiol 17-Î²-d-Glucuronide by Multidrug Resistance Protein 4. Journal of Biological Chemistry, 2001, 276, 33747-33754.	1.6	358
11	Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research, 2010, 70, 7981-7991.	0.4	297
12	Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2â€“Mediated Drug Resistance. Cancer Research, 2007, 67, 11012-11020.	0.4	280
13	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leukemia Research, 2010, 34, 1255-1268.	0.4	252
14	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Research, 2002, 62, 3144-50.	0.4	245
15	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Research, 2003, 63, 4048-54.	0.4	245
16	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS Journal, 2011, 278, 3226-3245.	2.2	222
17	Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer, 2012, 31, 58-72.	4.9	217
18	MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2â€²,3â€²-Dideoxycytidine and 9â€²-(2â€²-Phosphonylmethoxyethyl)adenine. Journal of Biological Chemistry, 2003, 278, 29509-29514.	1.6	215

#	Article	IF	Citations
19	Nilotinib (AMN107, TasignaÂ®) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochemical Pharmacology, 2009, 78, 153-161.	2.0	201
20	Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10). Cancer Research, 2004, 64, 4927-4930.	0.4	195
21	Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. Cancers, 2015, 7, 2360-2371.	1.7	194
22	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Research, 2002, 62, 6172-7.	0.4	190
23	Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 570-594.	0.9	185
24	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates, 2020, 48, 100663.	6.5	180
25	Multidrug Resistance and the Lung Resistance-Related Protein in Human Colon Carcinoma SW-620 Cells. Journal of the National Cancer Institute, 1999, 91, 1647-1653.	3.0	174
26	Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	1.0	167
27	Effect of Multidrug Resistance-Reversing Agents on Transporting Activity of Human Canalicular Multispecific Organic Anion Transporter. Molecular Pharmacology, 1999, 56, 1219-1228.	1.0	165
28	Analysis of the In Vivo Functions of Mrp3. Molecular Pharmacology, 2005, 68, 160-168.	1.0	161
29	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research, 2011, 71, 3029-3041.	0.4	157
30	Multidrug Resistance Proteins (MRPs) and Cancer Therapy. AAPS Journal, 2015, 17, 802-812.	2.2	155
31	Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resistance Updates, 2020, 49, 100681.	6.5	154
32	MRP subfamily transporters and resistance to anticancer agents. Journal of Bioenergetics and Biomembranes, 2001, 33, 493-501.	1.0	151
33	Chemical molecularâ€based approach to overcome multidrug resistance in cancer by targeting Pâ€glycoprotein (Pâ€gp). Medicinal Research Reviews, 2021, 41, 525-555.	5.0	150
34	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Molecular Cancer, 2019, 18, 23.	7.9	149
35	Transport of Bile Acids, Sulfated Steroids, Estradiol 17-Î²-d-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11). Molecular Pharmacology, 2005, 67, 545-557.	1.0	146
36	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates, 2012, 15, 70-80.	6.5	143

#	Article	IF	Citations
37	Enhanced transport of anticancer agents and leukotriene C4by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Letters, 1999, 456, 327-331.	1.3	141
38	m6A modification: recent advances, anticancer targeted drug discovery and beyond. Molecular Cancer, 2022, 21, 52.	7.9	138
39	Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biology and Therapy, 2006, 5, 39-47.	1.5	132
40	Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance. International Journal of Cancer, 2001, 93, 869-874.	2.3	128
41	ABCC10, ABCC11, and ABCC12. Pflugers Archiv European Journal of Physiology, 2007, 453, 675-684.	1.3	126
42	Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 255-265.	3.3	122
43	Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer, 2020, 19, 54.	7.9	120
44	Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B. Cancer Research, 2009, 69, 178-184.	0.4	118
45	Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Letters, 2009, 279, 74-83.	3.2	108
46	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates, 2020, 53, 100720.	6.5	107
47	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. Drug Resistance Updates, 2021, 54, 100743.	6.5	107
48	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Letters, 2013, 328, 307-317.	3.2	106
49	Role of ABC transporters in cancer chemotherapy. Chinese Journal of Cancer, 2012, 31, 51-57.	4.9	103
50	Therapeutic strategies to overcome taxane resistance in cancer. Drug Resistance Updates, 2021, 55, 100754.	6.5	103
51	Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules, 2014, 19, 13848-13877.	1.7	97
52	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters, 2018, 421, 186-198.	3.2	96
53	Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Research and Treatment, 2012, 135, 737-747.	1.1	95
54	Oncosis-inducing cyclometalated iridium(<scp>iii</scp>) complexes. Chemical Science, 2018, 9, 5183-5190.	3.7	95

#	Article	IF	Citations
55	The combination of disulfiram and copper for cancer treatment. Drug Discovery Today, 2020, 25, 1099-1108.	3.2	95
56	A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway. Journal of Medicinal Chemistry, 2017, 60, 1449-1468.	2.9	93
57	Novel nanomedicines to overcome cancer multidrug resistance. Drug Resistance Updates, 2021, 58, 100777.	6.5	93
58	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical Pharmacology, 2010, 79, 154-161.	2.0	89
59	RNA methylation and cancer treatment. Pharmacological Research, 2021, 174, 105937.	3.1	89
60	Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 3.	3.5	88
61	Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Molecular Pharmacology, 2012, 82, 47-58.	1.0	87
62	Discovery of Novel Quinolineâ€“Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. Journal of Medicinal Chemistry, 2019, 62, 993-1013.	2.9	84
63	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters, 2019, 440-441, 82-93.	3.2	83
64	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular Cancer Therapeutics, 2012, 11, 2033-2044.	1.9	81
65	Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens. Frontiers in Pharmacology, 2021, 12, 720726.	1.6	81
66	The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochemical Pharmacology, 2013, 85, 514-524.	2.0	80
67	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications, 2022, 13, 2672.	5.8	80
68	RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Letters, 2009, 276, 189-195.	3.2	76
69	miR200c Attenuates P-gpâ€“Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer. Molecular Cancer Therapeutics, 2014, 13, 3137-3151.	1.9	74
70	Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival. Clinical Cancer Research, 2009, 15, 1762-1769.	3.2	73
71	TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Epigenomics, 2016, 8, 651-666.	1.0	72
72	The PI3K subunits, P110Î± and P110Î² are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Molecular Cancer, 2020, 19, 10.	7.9	72

#	Article	IF	Citations
73	The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter. PLoS ONE, 2011, 6, e19329.	1.1	71
74	Proteomics technologies for cancer liquid biopsies. Molecular Cancer, 2022, 21, 53.	7.9	70
75	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochemical Pharmacology, 2009, 77, 781-793.	2.0	69
76	Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochemical Pharmacology, 2009, 77, 993-1001.	2.0	66
77	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduction and Targeted Therapy, 2020, 5, 193.	7.1	66
78	Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). PLoS ONE, 2009, 4, e7520.	1.1	65
79	Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discovery Today, 2021, 26, 1284-1292.	3.2	65
80	Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp.. Tetrahedron Letters, 1998, 39, 6303-6306.	0.7	63
81	Lamellarin O, a Pyrrole Alkaloid from an Australian Marine Sponge, Ianthella sp., Reverses BCRP Mediated Drug Resistance in Cancer Cells. Marine Drugs, 2014, 12, 3818-3837.	2.2	63
82	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Frontiers in Immunology, 2021, 12, 658519.	2.2	63
83	Reversing Effect of Agosterol A, a Spongean Sterol Acetate, on Multidrug Resistance in Human Carcinoma Cells. Japanese Journal of Cancer Research, 2001, 92, 886-895.	1.7	62
84	Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10â^'/â^' Mice. Cancer Research, 2011, 71, 3649-3657.	0.4	62
85	Autophagy and Transporter-Based Multi-Drug Resistance. Cells, 2012, 1, 558-575.	1.8	62
86	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochemical Pharmacology, 2012, 83, 1613-1622.	2.0	62
87	Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance. Marine Drugs, 2012, 10, 2312-2321.	2.2	61
88	Chloroquine against malaria, cancers and viral diseases. Drug Discovery Today, 2020, 25, 2012-2022.	3.2	61
89	Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers, 2014, 6, 1925-1952.	1.7	60
90	Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chinese Journal of Cancer, 2012, 31, 110-118.	4.9	60

#	Article	IF	Citations
91	Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Molecular Cancer, 2022, 21, 12.	7.9	60
92	Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol a on MRP1 function. International Journal of Cancer, 2001, 93, 107-113.	2.3	59
93	Triterpenoids as reversal agents for anticancer drug resistance treatment. Drug Discovery Today, 2014, 19, 482-488.	3.2	59
94	Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resistance Updates, 2021, 57, 100770.	6.5	59
95	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2010, 80, 1497-1506.	2.0	57
96	Roles of Sildenafil in Enhancing Drug Sensitivity in Cancer. Cancer Research, 2011, 71, 3735-3738.	0.4	57
97	ATPâ€binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine, 2021, 14, 232-256.	0.7	57
98	Glutathione-dependent Binding of a Photoaffinity Analog of Agosterol A to the C-terminal Half of Human Multidrug Resistance Protein. Journal of Biological Chemistry, 2001, 276, 23197-23206.	1.6	56
99	Sipholenol A, a marineâ€derived sipholane triterpene, potently reverses Pâ€glycoprotein (ABCB1)â€mediated multidrug resistance in cancer cells. Cancer Science, 2007, 98, 1373-1380.	1.7	56
100	Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria. Journal of Medicinal Chemistry, 2016, 59, 5022-5034.	2.9	56
101	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: InÂvitro and inÂvivo study. Cancer Letters, 2017, 396, 145-154.	3.2	56
102	Targeted Deletion of Both Thymidine Phosphorylase and Uridine Phosphorylase and Consequent Disorders in Mice. Molecular and Cellular Biology, 2002, 22, 5212-5221.	1.1	55
103	Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Sipholane Triterpenoids. Journal of Natural Products, 2007, 70, 928-931.	1.5	55
104	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. Journal of Medicinal Chemistry, 2018, 61, 5988-6001.	2.9	53
105	Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leukemia Research, 2008, 32, 799-809.	0.4	52
106	In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter <scp>MRP1</scp>. British Journal of Pharmacology, 2014, 171, 5845-5857.	2.7	52
107	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2019, 166, 120-127.	2.0	52
108	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. , 2020, 216, 107672.		52

#	Article	IF	Citations
109	Sipholane Triterpenoids: Chemistry, Reversal of ABCB1/P-Glycoprotein-Mediated Multidrug Resistance, and Pharmacophore Modeling. Journal of Natural Products, 2009, 72, 1291-1298.	1.5	51
110	Design and Synthesis of Human ABCB1 (P-Glycoprotein) Inhibitors by Peptide Coupling of Diverse Chemical Scaffolds on Carboxyl and Amino Termini of (S)-Valine-Derived Thiazole Amino Acid. Journal of Medicinal Chemistry, 2014, 57, 4058-4072.	2.9	51
111	Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochemical Pharmacology, 2014, 90, 367-378.	2.0	50
112	Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Molecular Cancer, 2020, 19, 147.	7.9	50
113	Novel Hybrids of Natural Oridonin-Bearing Nitrogen Mustards as Potential Anticancer Drug Candidates. ACS Medicinal Chemistry Letters, 2014, 5, 797-802.	1.3	49
114	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 189-199.	1.1	48
115	Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chinese Journal of Cancer, 2014, 33, 223-230.	4.9	48
116	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Scientific Reports, 2016, 6, 25694.	1.6	48
117	Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Cellular Physiology and Biochemistry, 2018, 45, 1515-1528.	1.1	48
118	An Active Efflux System for Heavy Metals in Cisplatin-Resistant Human KB Carcinoma Cells. Experimental Cell Research, 1998, 240, 312-320.	1.2	47
119	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical Pharmacology, 2014, 89, 52-61.	2.0	47
120	Î²-elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncology Reports, 2014, 31, 858-866.	1.2	47
121	Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Pharmacology, 2018, 9, 1097.	1.6	47
122	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochemical Pharmacology, 2018, 158, 274-285.	2.0	47
123	5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/Î²-catenin/MMP-7 signaling pathway. Oncotarget, 2015, 6, 25975-25987.	0.8	47
124	New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resistance Updates, 2022, 64, 100849.	6.5	47
125	Reversal of Heavy Metal Resistance in Multidrug-Resistant Human KB Carcinoma Cells. Biochemical and Biophysical Research Communications, 1997, 236, 586-590.	1.0	46
126	Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules, 2019, 24, 4383.	1.7	46

#	Article	IF	Citations
127	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NFâ€ÎºB Pathway in Colorectal Cancer. Journal of Cellular Biochemistry, 2016, 117, 1471-1481.	1.2	45
128	Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochemical Pharmacology, 2015, 93, 266-276.	2.0	44
129	Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Molecular Cancer, 2020, 19, 134.	7.9	44
130	BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistancein Vitroandin Vivo. Molecular Pharmaceutics, 2012, 9, 3147-3159.	2.3	43
131	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: InÂvitro and inÂvivo. Cancer Letters, 2018, 424, 19-29.	3.2	42
132	The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncology Reports, 2009, 21, 483-9.	1.2	42
133	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncology Reports, 2007, 17, 969-76.	1.2	42
134	Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Molecular Pharmaceutics, 2011, 8, 1687-1697.	2.3	41
135	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2018, 143, 1535-1542.	2.6	41
136	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. Frontiers in Pharmacology, 2018, 9, 1236.	1.6	41
137	Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters, 2019, 442, 91-103.	3.2	41
138	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	0.8	41
139	Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. Tetrahedron, 1999, 55, 13965-13972.	1.0	40
140	Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Molecular Cancer, 2022, 21, 37.	7.9	40
141	Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges. Frontiers in Oncology, 2022, 12, 867655.	1.3	40
142	Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10â€“Mediated Paclitaxel Resistance: A Preclinical Study. Molecular Cancer Therapeutics, 2014, 13, 714-723.	1.9	39
143	Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. Oncotarget, 2015, 6, 24277-24290.	0.8	38
144	The targeting of nonâ€‘coding RNAs by curcumin: Facts and hopes for cancer therapy (Review). Oncology Reports, 2019, 42, 20-34.	1.2	38

#	Article	IF	Citations
145	<scp>PDE</scp>5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (<scp>ATP</scp>â€binding Cassette <scp>C</scp>10) transporter. Cancer Science, 2012, 103, 1531-1537.	1.7	37
146	Saracatinib (AZD0530) is a potent modulator of ABCB1â€mediated multidrug resistance in vitro and in vivo. International Journal of Cancer, 2013, 132, 224-235.	2.3	37
147	Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncology Reports, 2013, 29, 2479-2485.	1.2	37
148	Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. Acta Biomaterialia, 2015, 25, 268-283.	4.1	37
149	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules, 2016, 21, 1236.	1.7	37
150	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers, 2020, 12, 466.	1.7	37
151	The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy. Drug Discovery Today, 2021, 26, 490-502.	3.2	37
152	Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202. Molecular Pharmaceutics, 2012, 9, 1971-1982.	2.3	35
153	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Letters, 2014, 350, 61-68.	3.2	35
154	Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer. Molecular Cancer, 2022, 21, 112.	7.9	35
155	Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. PLoS ONE, 2013, 8, e55576.	1.1	34
156	Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. International Journal of Oncology, 2015, 46, 2029-2038.	1.4	34
157	Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. Cancer Letters, 2019, 442, 104-112.	3.2	33
158	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	1.7	33
159	Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 2021, 64, 9120-9140.	2.9	33
160	Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Letters, 1998, 130, 175-182.	3.2	32
161	Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. Cancer Letters, 2017, 386, 100-109.	3.2	32
162	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1524-1535.	0.5	32

#	Article	IF	Citations
163	CDX2 Stimulates the Proliferation of Porcine Intestinal Epithelial Cells by Activating the mTORC1 and Wnt/β-Catenin Signaling Pathways. International Journal of Molecular Sciences, 2017, 18, 2447.	1.8	31
164	Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. Oncotarget, 2017, 8, 29760-29770.	0.8	31
165	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. Future Medicinal Chemistry, 2019, 11, 323-336.	1.1	31
166	Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. Frontiers in Public Health, 2021, 9, 671788.	1.3	31
167	Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Biochemical Pharmacology, 2013, 85, 1257-1268.	2.0	30
168	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. Molecular Cancer Therapeutics, 2017, 16, 1021-1030.	1.9	30
169	Characterization of the ATP-Dependent LTC4Transporter in Cisplatin-Resistant Human KB Cells. Biochemical and Biophysical Research Communications, 1996, 226, 158-165.	1.0	29
170	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. International Journal of Biochemistry and Cell Biology, 2014, 51, 111-119.	1.2	29
171	6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents. Journal of Natural Products, 2017, 80, 2391-2398.	1.5	29
172	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Frontiers in Oncology, 2019, 9, 514.	1.3	29
173	From Antimicrobial to Anticancer Peptides: The Transformation of Peptides. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 70-84.	0.8	29
174	Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Letters, 1998, 129, 69-76.	3.2	28
175	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncology, 2014, 10, 1827-1841.	1.1	28
176	Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. International Journal of Oncology, 2014, 44, 1634-1642.	1.4	28
177	The reversal of antineoplastic drug resistance in cancer cells by β-elemene. Chinese Journal of Cancer, 2015, 34, 488-95.	4.9	28
178	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. Biochemical Pharmacology, 2017, 132, 29-37.	2.0	28
179	Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. International Journal of Biochemistry and Cell Biology, 2019, 110, 21-28.	1.2	28
180	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 179, 849-862.	2.6	28

#	Article	IF	Citations
181	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2019, 9, 313.	1.3	28
182	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget, 2015, 6, 510-521.	0.8	28
183	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. Oncotarget, 2016, 7, 5877-5891.	0.8	28
184	Reversal of P-Glycoprotein and Multidrug-Resistance Protein-Mediated Drug Resistance in KB Cells by 5-O-Benzoylated Taxinine K. Molecular Pharmacology, 2000, 58, 1563-1569.	1.0	27
185	Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. Pharmacological Research, 2017, 119, 89-98.	3.1	27
186	Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates. International Journal of Molecular Sciences, 2019, 20, 268.	1.8	27
187	Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. Journal of Medicinal Chemistry, 2020, 63, 5458-5476.	2.9	27
188	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 14895-14911.	2.9	27
189	Proteome Analysis of Multidrug Resistance of Human Oral Squamous Carcinoma Cells Using CD147 Silencing. Journal of Proteome Research, 2008, 7, 4784-4791.	1.8	26
190	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology, 2009, 78, 355-364.	2.0	26
191	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncology Reports, 2014, 31, 1605-1612.	1.2	26
192	Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 2022, 12, 2193-2205.	5.7	26
193	Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Molecular Cancer, 2022, 21, 43.	7.9	26
194	Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. Journal of Medicinal Chemistry, 2018, 61, 834-864.	2.9	25
195	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. Journal of Medicinal Chemistry, 2020, 63, 15979-15996.	2.9	25
196	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. Frontiers in Oncology, 2020, 10, 700.	1.3	25
197	Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2020, 63, 8157-8178.	2.9	25
198	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 1387.	1.8	25

#	Article	IF	Citations
199	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resistance Updates, 2020, 52, 100703.	6.5	25
200	Fragmented polymer nanotubes from sonication-induced scission with a thermo-responsive gating system for anti-cancer drug delivery. Journal of Materials Chemistry B, 2014, 2, 1327-1334.	2.9	24
201	PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharmaceutica Sinica B, 2014, 4, 202-207.	5.7	24
202	PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Letters, 2016, 383, 220-229.	3.2	24
203	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications, 2020, 40, 285-300.	3.7	24
204	MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. Molecular Cancer, 2021, 20, 118.	7.9	24
205	Dual TTK/CLK2 inhibitor, CCâ€671, selectively antagonizes ABCG2â€mediated multidrug resistance in lung cancer cells. Cancer Science, 2020, 111, 2872-2882.	1.7	24
206	Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Anti-Cancer Drugs, 2012, 23, 865-873.	0.7	23
207	Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. European Journal of Pharmaceutical Sciences, 2013, 49, 441-450.	1.9	23
208	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Molecular Pharmacology, 2019, 96, 73-89.	1.0	23
209	A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer. Materials Science and Engineering C, 2020, 107, 110224.	3.8	23
210	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Frontiers in Pharmacology, 2020, 11, 1208.	1.6	23
211	The role of endolysosomal trafficking in anticancer drug resistance. Drug Resistance Updates, 2021, 57, 100769.	6.5	23
212	IKK inhibition increases bortezomib effectiveness in ovarian cancer. Oncotarget, 2015, 6, 26347-26358.	0.8	23
213	Cycloruthenated Selfâ€Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. Advanced Materials, 2022, 34, e2100245.	11.1	23
214	Fiberâ€Optic Theranostics (FOT): Interstitial Fiberâ€Optic Needles for Cancer Sensing and Therapy. Advanced Science, 2022, 9, e2200456.	5.6	23
215	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology, 2012, 84, 766-774.	2.0	22
216	Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. European Journal of Pharmacology, 2014, 733, 34-44.	1.7	22

#	Article	IF	Citations
217	Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. International Journal of Oncology, 2017, 51, 257-268.	1.4	22
218	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. European Journal of Pharmacology, 2019, 863, 172611.	1.7	22
219	BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells. PLoS ONE, 2013, 8, e54181.	1.1	22
220	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. Oncotarget, 2017, 8, 93785-93799.	0.8	22
221	WHI â€P154 enhances the chemotherapeutic effect of anticancer agents in ABCG 2â€overexpressing cells. Cancer Science, 2014, 105, 1071-1078.	1.7	21
222	GSK1904529A, a Potent IGFâ€IR Inhibitor, Reverses MRP1â€Mediated Multidrug Resistance. Journal of Cellular Biochemistry, 2017, 118, 3260-3267.	1.2	21
223	Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. Biochemical Pharmacology, 2020, 175, 113848.	2.0	21
224	Functional Comparison between YCF1 and MRP1 Expressed in Sf21 Insect Cells. Biochemical and Biophysical Research Communications, 2000, 270, 608-615.	1.0	20
225	A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDRin vitroandin vivo. Oncotarget, 2015, 6, 39276-39291.	0.8	20
226	Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 281-289.	1.5	20
227	The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo. Acta Pharmaceutica Sinica B, 2019, 9, 316-323.	5.7	20
228	Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4832-4837.	1.0	19
229	Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4698-4704.	1.0	19
230	A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor. International Journal of Nanomedicine, 2018, Volume 13, 8411-8427.	3.3	19
231	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4095.	1.8	19
232	Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia. Drug Discovery Today, 2021, 26, 1735-1743.	3.2	19
233	Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera. Pharmaceutical Research, 2022, 39, 2745-2759.	1.7	19
234	CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Molecular Cancer, 2022, 21, 103.	7.9	19

#	Article	IF	Citations
235	2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Frontiers in Pharmacology, 2022, 13, 899633.	1.6	19
236	Multidrug Resistance Reversal Activity of Taxoids fromTaxus cuspidatein KB-C2 and 2780AD Cells. Japanese Journal of Cancer Research, 2000, 91, 638-642.	1.7	18
237	Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7268-7271.	1.0	18
238	CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Biochemical Pharmacology, 2014, 91, 144-156.	2.0	18
239	ARRYâ€334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATPâ€Binding Cassette Subfamily G Member 2. Journal of Cellular Biochemistry, 2014, 115, 1381-1391.	1.2	18
240	Esters of the Marine-Derived Triterpene Sipholenol A Reverse P-GP-Mediated Drug Resistance. Marine Drugs, 2015, 13, 2267-2286.	2.2	18
241	Revisiting mTOR inhibitors as anticancer agents. Drug Discovery Today, 2019, 24, 2086-2095.	3.2	18
242	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. Protein and Cell, 2021, 12, 586-591.	4.8	18
243	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Frontiers in Cell and Developmental Biology, 2020, 8, 601400.	1.8	18
244	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Frontiers in Oncology, 2020, 10, 674.	1.3	18
245	Natural Products: A Promising Therapeutics for Targeting Tumor Angiogenesis. Frontiers in Oncology, 2021, 11, 772915.	1.3	18
246	B4G2 Induces Mitochondrial Apoptosis by the ROS-Mediated Opening of Ca2+-Dependent Permeability Transition Pores. Cellular Physiology and Biochemistry, 2015, 37, 838-852.	1.1	17
247	ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Chinese Journal of Cancer, 2015, 34, 115-20.	4.9	17
248	Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). Bioorganic and Medicinal Chemistry, 2018, 26, 5006-5017.	1.4	17
249	Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. Drug Discovery Today, 2021, 26, 2282-2302.	3.2	17
250	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget, 2015, 6, 17738-17752.	0.8	17
251	Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. Frontiers in Oncology, 2020, 10, 574861.	1.3	16
252	Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines. Frontiers in Pharmacology, 2022, 13, 850862.	1.6	16

#	Article	IF	Citations
253	An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. Cancer Letters, 1999, 138, 13-22.	3.2	15
254	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncology Reports, 0, , .	1.2	15
255	Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. Frontiers in Pharmacology, 2013, 4, 82.	1.6	15
256	Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. European Journal of Medicinal Chemistry, 2018, 149, 211-224.	2.6	15
257	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. Frontiers in Oncology, 2020, 10, 228.	1.3	15
258	Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. European Journal of Medicinal Chemistry, 2021, 216, 113316.	2.6	15
259	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 26-41.	0.8	15
260	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. MedComm, 2021, 2, 765-777.	3.1	15
261	Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharmaceutica Sinica B, 2017, 7, 564-570.	5.7	14
262	Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. Experimental Cell Research, 2020, 388, 111858.	1.2	14
263	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. Frontiers in Pharmacology, 2020, 11, 615824.	1.6	14
264	Drug resistance: from bacteria to cancer. Molecular Biomedicine, 2021, 2, 27.	1.7	14
265	Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. Journal of Medicinal Chemistry, 2021, 64, 16187-16204.	2.9	14
266	Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. Anticancer Research, 2014, 34, 4767-73.	0.5	14
267	BBA, a Synthetic Derivative of 23-hydroxybutulinic Acid, Reverses Multidrug Resistance by Inhibiting the Efflux Activity of MRP7 (ABCC10). PLoS ONE, 2013, 8, e74573.	1.1	13
268	Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacological Research, 2017, 121, 184-193.	3.1	13
269	Patterned synthesis of ZnO nanorod arrays for nanoplasmonic waveguide applications. Optics Communications, 2018, 411, 53-58.	1.0	13
270	Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 865.	1.8	13

#	Article	IF	Citations
271	Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. Frontiers in Oncology, 2020, 10, 624954.	1.3	13
272	A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study. Cancers, 2021, 13, 2565.	1.7	13
273	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. Journal of Biomedical Research, 2016, 30, 120-133.	0.7	13
274	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2021, 64, 17346-17365.	2.9	13
275	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. Frontiers in Pharmacology, 2021, 12, 732403.	1.6	13
276	Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis. Annals of the Rheumatic Diseases, 2022, 81, 544-555.	0.5	13
277	Quercetin ameliorates oxidative stressâ€induced cell apoptosis of seminal vesicles via activating Nrf2 in type 1 diabetic rats. Biomedicine and Pharmacotherapy, 2022, 151, 113108.	2.5	13
278	Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation â€“ Evaluation of intestinal absorption and anti-cancer activity. Journal of Molecular Liquids, 2021, 327, 114866.	2.3	12
279	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine and Pharmacotherapy, 2021, 136, 111223.	2.5	12
280	PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Molecular Cancer, 2022, 21, .	7.9	12
281	An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms. Chemical Communications, 2019, 55, 3833-3836.	2.2	11
282	Y6, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance. Frontiers in Pharmacology, 2018, 9, 1545.	1.6	11
283	A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway. Molecular Therapy - Oncolytics, 2020, 18, 137-148.	2.0	11
284	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. Frontiers in Oncology, 2020, 10, 1219.	1.3	11
285	BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 2502.	1.7	11
286	Overexpression of ABCC1 Confers Drug Resistance to Betulin. Frontiers in Oncology, 2021, 11, 640656.	1.3	11
287	The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. Drug Discovery Today, 2021, 26, 1293-1301.	3.2	11
288	Cytokine Detection by Flow Cytometry. Methods in Molecular Biology, 2014, 1172, 235-242.	0.4	11

#	Article	IF	Citations
289	Reconstruction of intestinal microecology of Type 2 diabetes by Fecal Microbiota Transplantation: Why and How. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	11
290	Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells. Anti-Cancer Drugs, 2013, 24, 441-454.	0.7	10
291	Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Scientific Reports, 2017, 7, 42106.	1.6	10
292	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Letters, 2020, 472, 132-141.	3.2	10
293	Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. Frontiers in Oncology, 2020, 10, 1732.	1.3	10
294	ABCG2 Overexpression Contributes to Pevonedistat Resistance. Cancers, 2020, 12, 429.	1.7	10
295	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences, 2021, 22, 2463.	1.8	10
296	TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 341-347.	0.8	10
297	Receptors and ligands for herpes simplex viruses: Novel insights for drug targeting. Drug Discovery Today, 2022, 27, 185-195.	3.2	10
298	New phenstatinâ€“fatty acid conjugates: Synthesis and evaluation. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5119-5122.	1.0	9
299	Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. Frontiers in Cell and Developmental Biology, 2020, 8, 607275.	1.8	9
300	Recent progress in antitumor functions of the intracellular antibodies. Drug Discovery Today, 2020, 25, 1109-1120.	3.2	9
301	Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model. Frontiers in Cell and Developmental Biology, 2021, 9, 640957.	1.8	9
302	Natural Product as Substrates of ABC Transporters: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 222-238.	0.8	9
303	Formulation and characterization of oleic acid magnetic PEG PLGA nanoparticles for targeting glioblastoma multiforme. Journal of Magnetism and Magnetic Materials, 2021, 533, 167970.	1.0	9
304	Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 177-186.	0.8	9
305	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. Oncology Reports, 2002, 9, 839-44.	1.2	9
306	The role of stem cell markers in multidrug resistance mediated by ABC transporters. Leukemia Research, 2010, 34, 696-697.	0.4	8

#	Article	IF	Citations
307	1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors. Cellular Physiology and Biochemistry, 2016, 38, 185-193.	1.1	8
308	Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Frontiers in Microbiology, 2020, 11, 1718.	1.5	8
309	Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. Journal of Natural Products, 2020, 83, 1563-1570.	1.5	8
310	Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. Frontiers in Oncology, 2020, 10, 932.	1.3	8
311	Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. Experimental Cell Research, 2020, 391, 111987.	1.2	8
312	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology, 2021, 12, 620874.	1.6	8
313	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Frontiers in Cell and Developmental Biology, 2021, 9, 697927.	1.8	8
314	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. Experimental Cell Research, 2021, 405, 112728.	1.2	8
315	Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 374.	3.5	8
316	Podophyllum hexandrum and its active constituents: Novel radioprotectants. Biomedicine and Pharmacotherapy, 2022, 146, 112555.	2.5	8
317	Tisotumab vedotin for the treatment of cervical carcinoma. Drugs of Today, 2022, 58, 213-222.	0.7	8
318	Correction: Reversal of Multidrug Resistance by Lapatinib. Cancer Research, 2008, 68, 10387-10387.	0.4	7
319	EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 1-11.		7
320	Insights on the structureâ€“function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. MedComm, 2021, 2, 221-235.	3.1	7
321	Recent progress on targeting leukemia stem cells. Drug Discovery Today, 2021, 26, 1904-1913.	3.2	7
322	Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells. Oncology Reports, 2007, 18, 721-7.	1.2	7
323	Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Drugs of Today, 2022, 58, 175-185.	0.7	7
324	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Frontiers in Pharmacology, 2022, 13, 861642.	1.6	7

#	Article	IF	Citations
325	The Potential Role of Exosomes in the Treatment of Brain Tumors, Recent Updates and Advances. Frontiers in Oncology, 2022, 12, 869929.	1.3	7
326	MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: InÂvitro and inÂvivo study. Acta Pharmaceutica Sinica B, 2022, 12, 2609-2618.	5.7	7
327	Editorial: Chemo-Radiation-Resistance in Cancer Therapy. Frontiers in Pharmacology, 0, 13, .	1.6	7
328	Editorial [Hot Topic: ABC Transporters in Pharmacology/Physiology and Human Diseases (Guest Editor:) Tj ETQq0 0 0 rgBT /Overlock 10	0.9	6
329	Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6495-6499.	1.0	6
330	Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia. Frontiers in Oncology, 2020, 10, 588641.	1.3	6
331	The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. Frontiers in Cell and Developmental Biology, 2021, 9, 649434.	1.8	6
332	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Frontiers in Oncology, 2021, 11, 731260.	1.3	6
333	Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro. Gastroenterology Report, 2020, 8, 465-475.	0.6	6
334	Ginsenoside Rg3 Promotes Cell Growth Through Activation of mTORC1. Frontiers in Cell and Developmental Biology, 2021, 9, 730309.	1.8	6
335	Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs. Frontiers in Cell and Developmental Biology, 2021, 9, 766371.	1.8	6
336	An Ayurgenomics Approach: Prakriti-Based Drug Discovery and Development for Personalized Care. Frontiers in Pharmacology, 2022, 13, 866827.	1.6	6
337	Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells. Oncology Letters, 2011, 2, 549-556.	0.8	5
338	Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3â€²-azido-3â€²-deoxythymidine as anticancer prodrugs. Bioorganic and Medicinal Chemistry, 2014, 22, 5747-5756.	1.4	5
339	2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations. Journal of Cellular Biochemistry, 2017, 118, 2420-2429.	1.2	5
340	Lipidâ€“Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers, 2020, 12, 498.	1.7	5
341	Tepotinib hydrochloride for the treatment of non-small cell lung cancer. Drugs of Today, 2021, 57, 265.	0.7	5
342	OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. Frontiers in Cell and Developmental Biology, 2021, 9, 652972.	1.8	5

#	Article	IF	Citations
343	CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). Biochemical Pharmacology, 2021, 190, 114652.	2.0	5
344	Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. Drugs of Today, 2021, 57, 621.	0.7	5
345	Design, synthesis and biological evaluation of selective survivin inhibitors. Journal of Biomedical Research, 2019, 33, 82.	0.7	5
346	Double-Coated Poly(butyl Cyanoacrylate) Nanoparticles as a Potential Carrier for Overcoming P-Gp- and BCRP-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Nanotechnology, 2021, 3, .	2.4	5
347	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. Molecular Cancer, 2022, 21, 40.	7.9	5
348	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Frontiers in Pharmacology, 2022, 13, 843829.	1.6	5
349	ERH Gene and Its Role in Cancer Cells. Frontiers in Oncology, 2022, 12, .	1.3	5
350	AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer. Frontiers in Oncology, 2021, 11, 680663.	1.3	4
351	Application of microfluidic chips in anticancer drug screening. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	4
352	VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. Cancers, 2021, 13, 4675.	1.7	4
353	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. International Journal of Biological Sciences, 2021, 17, 2652-2665.	2.6	4
354	Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells. Frontiers in Pharmacology, 2022, 13, 867128.	1.6	4
355	Therapeutic implication of carbon monoxide in drug resistant cancers. Biochemical Pharmacology, 2022, 201, 115061.	2.0	4
356	Prognostic and Therapeutic Values of Autophagy-related Genes in Triple-negative Breast Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 380-386.	0.8	3
357	Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin. European Journal of Medicinal Chemistry, 2022, 231, 114155.	2.6	3
358	Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). Pakistan Journal of Pharmaceutical Sciences, 2013, 26, 1151-6.	0.2	3
359	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. Frontiers in Pharmacology, 2022, 13, 843110.	1.6	3
360	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. Oncology Reports, 2002, 9, 839.	1.2	2

#	Article	IF	Citations
361	Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells. Anti-Cancer Drugs, 2007, 18, 1015-1021.	0.7	2
362	ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 183-208.	0.1	2
363	Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7. , 2020, , .		2
364	Anticancer Activity of Oldenlandia Diffusa & Viola Philippica Car. Journal of Cancer Research Updates, 0, , .	0.3	2
365	Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, .	0.8	2
366	The Discovery of Novel PGK1 Activators as Apoptotic Inhibiting and Neuroprotective Agents. Frontiers in Pharmacology, 2022, 13, 877706.	1.6	2
367	Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure. Signal Transduction and Targeted Therapy, 2022, 7, 89.	7.1	2
368	Lurbinectedin for the treatment of small cell lung cancer. Drugs of Today, 2021, 57, 377.	0.7	1
369	Synthesis and anticancer evaluation of sulfur containing 9-anilinoacridines. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, .	0.8	1
370	Abstract 4432: A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. , 2015, , .		1
371	Abstract 3796: Selonsertib, an ASK1 inhibitor, antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Research, 2019, 79, 3796-3796.	0.4	1
372	Abstract 3006: Anticancer and multidrug resistance-reversing activities of novel antimicrobial peptides. , 2020, , .		1
373	Abstract 3010: VKNG 1 reverses multidrug resistance by inhibiting ABCG2 mediated drug transport in vitro and in vivo. , 2020, , .		1
374	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. Journal of Cancer Research Updates, 2014, 3, 169-173.	0.3	1
375	Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway. Journal of Cancer Research Updates, 2015, 4, 47-53.	0.3	1
376	Anticancer Activity of Five Traditionally Used Medicinal Plants' Extracts. Journal of Cancer Research Updates, 2014, 3, .	0.3	1
377	Paclitaxel and chemoresistance. , 2022, , 251-267.		1
378	Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances. Drugs of Today, 2022, 58, 117-132.	0.7	1

#	Article	IF	Citations
379	Mechanism of N-Methyl-N-Nitroso-Urea-Induced Gastric Precancerous Lesions in Mice. Journal of Oncology, 2022, 2022, 1-9.	0.6	1
380	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells. Frontiers in Oncology, 2022, 12, 855570.	1.3	1
381	The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms. Frontiers in Oncology, 0, 12, .	1.3	1
382	P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. , 2015, , 593-619.		0
383	Erratum to â€œDiscovery of a Non-toxic [1,2,4] Triazolo[1,5-A] Pyrimidin-7-One (WS-10) that Modulates ABCB1-Mediated Multidrug Resistance (MDR)â€•[Bioorganic & Medicinal Chemistry 26/18 (2018) 5006â€“5017]. Bioorganic and Medicinal Chemistry, 2018, 26, 5973.	1.4	0
384	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 13-27.		0
385	The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML. , 2021, , .		0
386	Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 44-53.	0.8	0
387	Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	0
388	CUL4high Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. American Journal of Pathology, 2021, 191, 1638-1650.	1.9	0
389	Vemurafenib (PLX4032, ZelborafÂ®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance. Journal of Cancer Research Updates, 0, , .	0.3	0
390	B5H7, a Morpholine Derivative of 23-Hydroxybetulinic Acid, Reverses Doxorubicin Resistance in HepG2/ADM. Journal of Cancer Research Updates, 0, , .	0.3	0
391	Icotinib improves progression free survival in epidermal growth factor receptor positive non-small cell lung cancer patients. Translational Cancer Research, 2018, 7, S26-S30.	0.4	0
392	Pharmacotherapeutic Options for Philadelphia Chromosome- Positive CML. Journal of Cancer Research Updates, 2018, 7, 49-58.	0.3	0
393	Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy. , 2022, , 269-286.		0
394	Research progress in overcoming ibrutinib drug resistance. Drugs of Today, 2022, 58, 85-94.	0.7	0
395	Editorial: Novel Molecular Mechanisms and Innovative Therapeutic Approaches for Age-Associated Diseases. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	0